Overview
Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119)
Status:
Completed
Completed
Trial end date:
2006-11-01
2006-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Interleukin-2 (IL-2) increases the number of CD4 cells in HIV-1 infected patients under highly active antiretroviral therapy (HAART) with a CD4 cell count over 200/mm3, but its activity in patients without antiretroviral therapy is unknown. This study will test the efficacy and safety of IL-2 in naïve patients with a CD4 count between 300 and 500/m3.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
French National Agency for Research on AIDS and Viral HepatitisCollaborator:
Chiron CorporationTreatments:
Interleukin-2
Criteria
Inclusion Criteria:- Adult patients with proven HIV-1-infection
- No prior exposition to antiretrovirals
- CD4 cell count between 300 and 500/mm3
- Signed written inform consent
Exclusion Criteria:
- Pregnancy